Original Research Article

Dexmedetomidine as an adjuvant for extension of postoperative analgesia in ropivacaine induced supraclavicular brachial plexus block

Mahendra Vangani1, Deepak Soni2, *

1 Dept. of Anesthesiology, Sri Aurobindo Medical College and PG Institute, Indore, Madhya Pradesh, India
2 Dept. of Anesthesiology, Employee’s State Insurance Corporation Medical College, Alwar, Rajasthan, India

ARTICLE INFO

Article history:
Received 29-04-2021
Accepted 08-05-2021
Available online 01-06-2021

Keywords:
Dexmedetomidine
Postoperative
Analgesia
Supraclavicular plexus

ABSTRACT

Background & Method: Pain is recognized as the fifth vital sign. The pain must be adequately treated esp. in postoperative period. The study was carried out at Department of Anesthesiology, Sri Aurobindo Institute of Medical Sciences Indore. The aim of the study was to assess the role of Dexmedetomidine in extension of post-operative analgesia. The study included 88 participants who were equally divided randomly into two groups i.e. with and without Dexmedetomidine intervention after the inclusion and exclusion criteria’s.

Result: The duration of post-operative analgesia in both groups indicating that contemplated surgery could be finished without need for additional analgesic supplement as the minimum and maximum time for surgery were within the range of effective analgesia without movement of limb. The time for demand of dose of rescue analgesics by the patients in both groups was 493.6±48.6 minutes and 961.0±141.6 minutes. The Dexmedetomidine group had a less demand of rescue analgesics. (P = 0.000). Whereas 23(52.2%) patients of Nonintervention group needed 2 to 4 doses of injection of diclofenac sodium by intramuscular route to control pain.

Conclusion: Addition of Dexmedetomidine 100 mcg to ropivacaine 0.5% solution for conduct of supraclavicular block improved the block quality and provided prolonged postoperative pain free period and decreased the demand of systemic analgesics.

© This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

1. Introduction

Brachial plexus blocks provide alternative for general anesthesia for upper limb surgeries and provide ideal operative conditions. Various drugs have been used as adjuvants to modify the block in terms of onset, quality, duration and post-operative analgesia. Bupivacaine is the most frequently used local anesthetic due to its long duration of action (4-8 hours). Adjuvants of recent interest include alpha 2 agonists- like clonidine, dexmedetomidine.

Clonidine, an α2-adrenergic agonist, has been used as an adjuvant to local anesthetics in regional anesthesia. It is demonstrated that adding clonidine to intermediate and long-acting local anesthetics during a single-shot peripheral nerve or nerve plexus block provides a longer duration of analgesia and motor blockade by approximately 2 hours.

Dexmedetomidine is a dextro-enantiomer and active component of medetomidine approved as intravenous sedative and co analgesic drug. Its alpha2/alpha1 selectivity ratio is 8 times than that of clonidine.

Studies comparing clonidine and dexmedetomidine an adjuvant to bupivacaine are reported in literature for blind technique of supraclavicular brachial plexus block. High dose of alpha-2 agonists is associated with side effects like hypotension and bradycardia. Very few studies have so far compared low dose of clonidine and dexmedetomidine.

Among the different techniques of supraclavicular brachial plexus block, the classical approach using paresthesia being a blind technique is associated with higher failure rates, injury to nerves and vascular structures. The requirement of higher volume and concentration of local...
2. Materials and Methods

The aim of the present study is to assess the role of Dexmedetomidine in extension of post-operative analgesia and also its intraoperative effects in ropivacaine induced supraclavicular brachial plexus block. The study was carried out at Department of Anesthesiology, Sri Aurobindo Institute of Medical Sciences Indore. The randomized controlled study involves observations on 88 patients of ASA grade I and II between age group 20-50 years, scheduled to undergo orthopedics surgery. After the approval from the hospital ethics committee and with the consent from the participants the study was carried out.

2.1. Inclusion criteria

1. Patients belonging to physical status classification I and II as per American society of Anesthesiologists.
2. Age group 20-50 years of both sexes.
3. Patients schedule patients scheduled for elective upper limb orthopedic surgery.

2.2. Exclusion criteria

1. Patient with known hypersensitivity to study drugs.
2. Infection at the site of block.
3. Patient with known coagulopathy or patient on anticoagulants.
4. Patients with severe systemic disorder (respiratory, cardiac, hepatic, renal diseases).
5. Pregnant and lactating women.
6. Patients with neurological, psychiatric or neurovascular disorder.
7. Patients belonging to physical status classification III and IV as per American society of anesthesiologists.

2.3. Drop out arrangement

The patients who did not had complete effect of brachial plexus block to allow surgery even after 20-30 minutes of block administration were withdrawn from the study and a new patient fulfilling inclusion criteria was recruited.

2.4. Study procedure

Patients were evaluated thoroughly in preanesthetic checkup a day prior to surgery. During the pre-anesthetic evaluation a General and systemic examination was done. During the Preoperative visit, anesthesia procedure to be undertaken was explained to the patients to alleviate the fear and anxiety of the patients. The participants were explained how to quantify their pain on visual analog scale. Airway assessment was also carried out in instances of failed block and need to administer general anesthesia.

Routine laboratory tests were conducted to rule out co-morbid conditions that included complete hemogram, blood counts, urine analysis, fasting and post meal glucose estimation and serum creatinine and whenever preoperative history suggested, coagulation profile, ECG and chest X-ray was done.

A written consent was obtained after counseling and explaining the procedure for inclusion in the study. Patients were instructed not to take anything orally for 6-8 hours before surgery. Availability of necessary resuscitation equipment, Anesthesia machine gas inlets connected to pipeline supply and drugs needed for administration of general anesthesia was confirmed. Intravenous access was established in the limb opposite to that undergoing surgery with 18 G cannula. The dose of dexmedetomidine was standardized and was administered accordingly to patients. The consented patients were divided randomly in to 2 groups. Both the groups were distributed randomly along with age, gender and other parameters matched. One of the groups was given Dexmedetomidine as an adjuvant to extend post-operative analgesia while other group was not given anything other than routine medications. Among the two groups, Group A was without Dexmedetomidine (without intervention) and Group B with Dexmedetomidine (with intervention).

2.5. Sample size

To calculate the sample size based on the prevalence with 99% confidence level, we used the following formula:

\[ n = \frac{Z^2 \cdot P \cdot (100-P)}{d^2} \]

Where

- \( Z = 2.58 \) AT 95% Confidence interval
- \( P = 7\% \) (prevalence of complication bradycardia in Group D 7\% ref. no...)
- \( L = \) absolute error = 10\%
- \( n = (2.58*2.58)*7*(100-7)/10*10 \)

4 Cases in each group total sample size 44+44=88.

The minimum sample size calculated by this formula was 88. But the sample size was rounded to 100 for increasing the power of the study. Therefore, the observations were made on 100 patients by including 50 patients in each group.
3. Results

Table 1 shows the distribution of age of the patients included in the study. The mean age of patients included in both groups was comparable, for group 1 it was 35.8 ± 9.9 years and 34.8±9.7 years. The table also shows mean weight of the patients included in the study. The mean weight of the patients in both groups was similar. The p value is 0.620 for age and 0.754 for weight respectively. So, there is no significant difference between two groups. Hence both groups were comparable.

Table 2 shows the sex distribution of the patients included in the study in both groups. In group 1; 34 were males & 10 were female and in group 2; 32 were males & 12 were female patients. The p value among two groups wrt to males and females was 0.613 and 0.730 respectively. So, no significant difference among two groups and were comparable.

Table 3 shows the onset characters of brachial plexus block. The mean onset time for sensory block in group 1 patients was observed as 19.8 with standard deviation of 1.3 minutes and for group 2 patients it was 17.0 and standard deviation of 0.8 minutes. We observed onset Mean time with Standard deviation was for motor block in group 1 and 2 was 22.3 ± 1.3 and 19.7 ± 0.9 minutes respectively. Above observations clearly shows that the onset of both sensory and motor block occurred earlier in patients who received dexmedetomidine along with ropivacaine and was found statistically significant between two groups.

Table 4 shows time of sensory and motor block in both groups. Duration of sensory and motor block in group 1 patients was 432.7 ± 39.5 and 344.3 ± 35.2 minutes respectively whereas the duration of sensory and motor block for the patients receiving dexmedetomidine 100 mcg (group 2 patients) was 896.±146.4 and 964.0±153.9 minutes. This observation clearly establishes that the difference in duration of block served was more than those who did not received dexmedetomidine. The statistical analysis revealed these changes to be highly significant. (P=0.000)

Table 5 shows the duration of post-operative analgesia in both groups indicating that contemplated surgery could be finished without need for additional analgesic supplement as the minimum and maximum time for surgery were within the range of effective analgesia without movement of limb. The time for demand of dose of rescue analgesic by the patients in both groups was 493.6±48.6 minutes and 961.0±141.6 minutes higher in patients who received dexmedetomidine and was found statistically significant (P = 0.000).

Table 6 shows the duration of surgery. In group 2 with dexmedetomidine the duration of surgery had a maximum duration of 210 min while without dexmedetomidine it was 140 mins. Hence this shows that with dexmedetomidine if required the surgery can be prolonged effectively.

Table 7 shows the number of rescue analgesics in first 24 hours in postoperative period. Whereas 23(52.2%) patients of group 1 (without Dexmedetomidine) needed 2 to 4 doses of injection of diclofenac sodium by intramuscular route to control pain but only 7(15.9%) patients of group 2 (with Dexmedetomidine) needed one rescue dose of diclofenac sodium for pain when VAS score was greater than 5.

4. Discussion

Managing postoperative pain has always been a challenge to the field of Anesthesia. Various studies done across the globe have suggested that post-surgical pain is one of the most common and most difficult to manage. Various drugs and methods have been tried and will continue to be tried until a patient satisfactory analgesia is achieved. Providing the patients with adequate postoperative pain relief is the need of the hour. In the current study, we have assessed the efficacy of Dexmedetomidine in post-operative analgesia.

The mean age of patients included in both groups was comparable i.e for non-intervention group 35.8 ± 9.9 years and for intervention group 34.8±9.7 years. Samina Ismail et al. studied post-operative pain management after caesarean section in 120 patients with age group 23 to 31 years with 65.2 kg and 63.8 kg in pethidine (PCA) group and Pethidine (continuous iv drip) group respectively. In Mitsuhat H et al. the mean age was 35.8 yrs. in IV group and 38.1 yrs. in Epidural group. In Altindis NT et al. study the mean age in Pethidine (Group I) was 58.1yrs & while 56.8yrs in group II (Dexmedetomidine). The average time for onset of sensory block in group 1 patients was observed as 19.8 with standard deviation of 1.3 minutes and for group 2 patients it was 17.0 and standard deviation of 0.8 minutes & similarly observed Mean time of onset with Standard deviation was for motor block in group 1 and 2 was 22.3 ± 1.3 and 19.7 ± 0.9 minutes respectively. The duration of sensory and motor block in group 1 patients without intervention was 432.7 ± 39.5 and 344.3 ± 35.2 minutes respectively whereas the duration of sensory and motor block for the patients
### Table 2:

| Sex           | Group 1 | Group 2 | Total | t value | p value |
|---------------|---------|---------|-------|---------|---------|
| Female        | 12 (46.2%) | 14 (53.8%) | 26 (100%) | 0.282 | 0.730 |
| Male          | 37 (50%) | 37 (50%) | 74 (100%) | 0.510 | 0.613 |
| Total         | 50      | 50      | 100    |         |         |

### Table 3:

| Variables                      | Group | No. of Patients | Mean  | Std. Deviation | T     | P     |
|--------------------------------|-------|----------------|-------|----------------|-------|-------|
| Onset time of Sensory Block    | Group 1 | 50             | 19.8  | 1.3            | 12.145 | 0.000 |
|                                | Group 2 | 50             | 17.0  | 0.8            |       |       |
| Onset time Motor Block         | Group 1 | 50             | 22.3  | 1.3            | 10.246 | 0.000 |
|                                | Group 2 | 50             | 19.7  | 0.9            |       |       |

### Table 4:

| Variables                      | Group | No. of Patients | Mean  | Std. Deviation | T     | P     |
|--------------------------------|-------|----------------|-------|----------------|-------|-------|
| Duration of effectiveness Sensory Block | Group 1 | 50             | 432.7 | 39.5           | 20.294 | 0.000 |
|                                | Group 2 | 50             | 896.8 | 146.4          |       |       |
| Duration of effectiveness Motor Block | Group 1 | 50             | 344.3 | 35.2           | 26.036 | 0.000 |
|                                | Group 2 | 50             | 964.0 | 153.9          |       |       |

### Table 5:

| Variables                      | Group | No. of Patients | Mean  | Std. Deviation | T     | P     |
|--------------------------------|-------|----------------|-------|----------------|-------|-------|
| Time of first rescue analgesic (min) | Group 1 | 50             | 493.6 | 48.6           | 20.702 | 0.000 |
|                                | Group 2 | 50             | 961.0 | 141.6          |       |       |

### Table 6: Duration of surgery

| Variables                      | Group | Group 1 | Group 2 |
|--------------------------------|-------|---------|---------|
| Duration of Surgery            |       |         |         |
| 00-60                          | 08    |         | 04      |
| 61-120                         | 26    |         | 27      |
| 121-180                        | 16    |         | 15      |
| 181-240                        | 00    |         | 02      |
| Total                          | 50    |         | 50      |
| Surgery with minimum duration (min) |       | 60      | 90      |
| Surgery with maximum Duration (min) |       | 140     | 210     |

### Table 7: Dose requirement of rescue analgesics in 24 hours

| Number of doses | Number of patients Group 1 | Number of patients Group 2 |
|-----------------|-----------------------------|-----------------------------|
| 1               | 21                          | 07                          |
| 2               | 11                          | 00                          |
| 3               | 08                          | 00                          |
| 4               | 04                          | 00                          |
receiving dexmedetomidine 100 mcg (group 2 patients) was 896.4±146.4 and 964.0±153.9 minutes. Addition of dexmedetomidine to ropivacaine has shown faster onset of sensory as well as motor block (17.0 ± 8.0 and 19.7± 0.9 minutes) as compared to ropivacaine (19.8 ± 1.3 and 22.3 ± 1.3 minutes) alone. Duration of motor block is also significantly prolonged. VAS scores decreased significantly in patients receiving dexmedetomidine with ropivacaine so also the demand of rescue dose of systemic analgesic. In both groups of patients remain hemodynamically stable, as compared to patients who received plain ropivacaine the heart rate and the blood pressure remains on the lower side for patients who received dexmedetomidine as an adjuvant to ropivacaine. Addition of dexmedetomidine to 0.5% ropivacaine causes mild sedation of the score 2 or 3 in which patient can respond to verbal commands

Zhang Y et al. studied the effect of using different doses of dexmedetomidine and found that increasing the dose from 50 to 100 mcg with ropivacaine, the incidences of bradycardia and hypo/hypertension was noted. Similarly, study done by Fritsch G et al. noted occurrence bradycardia among the patients with Dexmedetomidine but blood pressure remained stable. Anjan Das et al. also reported bradycardia in their patients with Dexmedetomidine. Elyazed MMA & Mogahed MM compared dexmedetomidine with magnesium sulphate used along with ropivacaine and found higher incidence of intraoperative bradycardia and hypotension with Dexmedetomidine.

The study also observed and recorded the complications related to test drug and procedure in the present study we noted incidences of bradycardia and hypotension attributable to the central and peripheral action of dexmedetomidine. The incidence of procedure related complications like local hematoma, postoperative pneumothorax or inadvertent intravascular injection of local anesthetic and hemiparesis of diaphragm were nil.

5. Conclusion

To conclude, the addition of Dexmedetomidine100 mcg to ropivacaine 0.5% solution for conduct of supraclavicular block improved the block quality and provided prolonged postoperative pain free period and decreased the demand of Systemic analgesics.

6. Conflict of Interest

None.

7. Source of Funding

None.

References

1. Chandak AA, Thaker JA, Kapdi MS. A Comparative Study of Bupivacaine, Bupivacaine with Dexmedetomidine and Bupivacaine with Fentanyl in Spinal Anaesthesia for Lower Abdominal Surgery. Med Sci. 2013;2(6):422–4.

2. Murrell JC, Helbækkers L.J. Medetomidine and dexmedetomidine: a review of cardiovascular effects and antinociceptive properties in the dog. Vet Anaesth Analg. 2005;32:117–27.

3. Martin E, Ramsay G, Mantz J, Sum-Ping STJ. The role of the alpha2-adrenoceptor agonist dexmedetomidine in postsurgical sedation in the intensive care unit. J Intensive Care Med. 2003;18:29–41.

4. Singh S, Goyal R, Upadhyay KK, Sethi N, Sharma RM, Sharma A. An evaluation of brachial plexus block using a nerve stimulator versus ultrasound guidance: a randomized controlled trial. J Anaesthesiol Clin Pharmacol. 2015;31(3):370.

5. Marhofer P, Greher M, Kapral S. Ultrasound guidance in regional anaesthesia. Br J Anaesth. 2005;94(1):7–17.

6. Abdelhaq MM, Kamal AM, Elramey MA. Different Volumes of Local Anesthetics in Ultrasound-Guided Combined Interscalene-Supraclavicular Block for Traumatic Humeral Fracture. Open J Anesthesiol. 2016;6(04):55.

7. Snell RS. Clinical anatomy by regions. 9th ed. Philadelphia: Lippincott Williams & Wilkins; 2012.

8. Winnie AP. Plexus Anesthesia. In: Historical considerations. Philadelphia: WB Saunders; 1983.

9. Ismail S, Afshan G, Monem A, Ahmed A. Postoperative analgesia for caesarean section: comparison of patient controlled analgesia with continuous infusion using pethidine. Br J Anaesth. 2012;2:120–6.

10. Muthuhahta H, Matsumoto S, Hasegawa J, Ohta K. Continuous intravenous pethidine infusion for analgesia after upper abdominal surgery: a randomized, prospective double-blind comparison with continuous epidural infusion of pethidine. Masui. 1991;40(12):1770–6.

11. Akindis NT, Karassian D, Peker TT, Ozmen S, Bulbul M. Comparison of meperidine alone with meperidine plus dexmedetomidine for postoperative patient-controlled analgesia. Neurosci. 2008;13(2):117–21.

12. Zhang X, Zhao X, Wang Y. Dexmedetomidine: a review of applications for cardiac surgery during perioperative period. J Anesth. 2014;29(1):102–11.

13. Fritsch G, Danninger T, Allerberger K, Tsodikov A, Felder TK, Kapeller M, et al. Dexmedetomidine added to ropivacaine extends the duration of interscalene brachial plexus blocks for elective shoulder surgery when compared with ropivacaine alone: a single-center, prospective, triple-blind, randomized controlled trial. Reg Anesth Pain Med. 2014;39(1):37–47.

14. Das A, Majumdar S, Halder S, Chattopadhyay S, Pal S, Kundu R. Effect of dexmedetomidine as adjuvant in ropivacaine-induced supraclavicular brachial plexus block: A prospective, double-blinded and randomized controlled study. Saudi J Anaesth. 2014;8:72–7.

15. Elyazed MMA, Mogahed MM. Comparison of Magnesium Sulfate and Dexmedetomidine as an Adjuvant to 0.5% Ropivacaine in Infraclavicular Brachial Plexus Block. Anesth Essays Res. 2018;12(1):109–15.

Author biography

Mahendra Vangani, Assistant Professor
Deepak Soni, Assistant Professor

Cite this article: Vangani M, Soni D. Dexmedetomidine as an adjuvant for extension of postoperative analgesia in ropivacaine induced supraclavicular brachial plexus block. Indian J Clin Anaesth 2021;8(2):265–269.